COVID-19 UPDATE

As a company, we are in close contact with the wholesalers and distributors to ensure they have adequate stock of our products for Gablofen®️ (baclofen for injection). We are in close contact with our manufacturing sites and the suppliers of our Active Pharmaceutical Ingredients (API) and components, so that we can sustain ongoing supply levels to support you. Please review our customer letter here.

Training & Education Programs

Get Started with Gablofen® (baclofen injection)

To help you and your practice get started with Gablofen®, we offer comprehensive on-site training, education on best use practices, and ongoing clinician support.

To request a program in your area, reach out to your local Gablofen representative now!

Educational Programs

A Clinical Discussion on the Challenges of Spasticity and Intrathecal Baclofen (ITB*) Management in Private Practice

New Dates & Times Coming Soon! 

This will be a Webinar Panel Discussion based on:

  • Practice Management Issues in times of COVID-19
  • Spasticity Management Issues
  • ITB Baclofen & Pump Issues

Moderator:
Dr. Andrea Toomer MD

Panel:
Dr. Lizette Alvarez MD
Dr. Atul T. Patel MD,  MHSA

Register: Coming Soon.

 

The Challenges of Spasticity and Intrathecal Baclofen (ITB*) Management in Pediatrics!

New Dates & Time Coming Soon! 

This will be a Webinar Panel Discussion based on:

  • Spasticity Management Issues in times of COVID-19
  • ITB Dosing Patterns
  • ITB Catheter & Pump Troubleshooting

*ITB Therapy is an established and widely accepted treatment option for severe spasticity.

Moderator:
Dr. Elizabeth Moberg-Wolff, MD, FAAPMR

Panel:
Dr. Reza Farid, MD
Dr. Andrew Skalsky, MD
Dr. Kathleen Kolaski, MD

Register: Coming Soon.

Invitation: The Challenges of Spasticity and Intrathecal Baclofen (ITB*) Management in Pediatrics! View now

Intrathecal Baclofen Best Practices!

New Dates & Times Coming Soon! 

This will be a Webinar Panel Discussion based on *The ITB Best Practices Project:

Program Description and Objectives:
Patient Selection/Screening Test/Management/Troubleshooting.
ITB Therapy is an established and widely accepted treatment option for severe spasticity.

*Reference:
The ITB Best Practices Project Consists of 4 Manuscripts that were Published in Neuromodulation 2016:  Patient Selection/Screening Test/Dosing and Long-Term Management and Troubleshooting.

Moderator:
Laurel Short, DNP, FNP-C

Panel:
Mary Elizabeth Nelson, DNP, ANP-BC
Tami McMichael, MS, CPNP AC-PC
Cassi D. Bodenheimer, RN

Invitation: Intrathecal Baclofen Best Practices! View now

Defining ITB Therapy and Best Practices

New Dates & Times Coming Soon! 

Program Description and Objectives:
Severe spasticity of spinal or cerebral origin is challenging to control effectively. ITB Therapy is an established and widely accepted treatment option for severe spasticity and has been proven useful for long-term control for some patients. Comprehension of consensus statements and practice guidelines aid in the safe and effective delivery of ITB therapy.

This program will focus on:

  • Defining ITB Therapy and appropriate candidates
  • Best practices for ITB Therapy processes
  • ITB Therapy clinical, safety, & cost-effectiveness data for indicated spasticity patients

Featuring:
Chris Cronsell, MD
Director of Neurorehabilitation
Center for Neurological Disorders, Ascension, Saint Francis Hospital

Invitation: Defining ITB Therapy and Best Practices! View now

Order Gablofen Today View Resource Gallery

Indications and Usage

  • Gablofen® (baclofen injection) is a gamma-aminobutyric acid (GABA) ergic agonist indicated for use in the management of severe spasticity of cerebral or spinal origin in adult and pediatric patients age 4 years and above.
  • Gablofen should be reserved for patients unresponsive to oral baclofen therapy, or those who experience intolerable central nervous system side effects at effective doses.
  • Patients should first respond to a screening dose of intrathecal baclofen prior to consideration for long term infusion via an implantable pump.
  • Spasticity due to traumatic brain injury: wait at least one year after injury before considering Gablofen therapy.

IMPORTANT RISK INFORMATION

WARNING: DO NOT DISCONTINUE ABRUPTLY

See full prescribing information for complete boxed warning

Abrupt discontinuation of intrathecal baclofen, regardless of the cause, has resulted in sequelae that include high fever, altered mental status, exaggerated rebound spasticity, and muscle rigidity, that in rare cases has advanced to rhabdomyolysis, multiple organ-system failure and death.

Prevention of abrupt discontinuation of intrathecal baclofen requires careful attention to programming and monitoring of the infusion system, refill scheduling and procedures, and pump alarms. Patients and caregivers should be advised of the importance of keeping scheduled refill visits and should be educated on the early symptoms of baclofen withdrawal. Special attention should be given to patients at apparent risk (e.g. spinal cord injuries at T-6 or above, communication difficulties, history of withdrawal symptoms from oral or intrathecal baclofen). Consult the technical manual of the implantable infusion system for additional post-implant clinician and patient information.

CONTRAINDICATIONS

  • Hypersensitivity to baclofen.
  • Do not use Gablofen for intravenous, intramuscular, subcutaneous or epidural administration.

WARNINGS AND PRECAUTIONS

  • Risk of life-threatening overdose during pump refills. Use extreme caution when filling the Medtronic SynchroMed® II Programmable Pump which is equipped with an injection port that allows direct access to the intrathecal catheter. Direct injection into the catheter through the catheter access port may cause a life-threatening overdose.
  • Use only with Medtronic SynchroMed® II Programmable Pump (or other pumps labeled for intrathecal administration of Gablofen (baclofen injection)).
  • Potential for contamination due to non-sterile external surface of prefilled syringe. Although the drug solution and pathway in the Gablofen prefilled syringes are sterile, the external surface of the prefilled syringes (all strengths, including the 50 mcg/mL strength) are non-sterile and have the potential to lead to contamination and consequent adverse reactions. The use of Gablofen prefilled syringe in an aseptic setting (e.g., operating room) to fill sterile intrathecal pumps prior to implantation in patients is not recommended, unless the external surface of the prefilled syringe is treated to ensure sterility. Gablofen supplied in vials may be used with conventional aseptic technique to fill intrathecal pumps prior to implantation.
  • Resuscitative equipment and trained staff must be available during screening dose, dose titration, and refills due to the potential life-threatening CNS depression, cardiovascular collapse, and/or respiratory failure.
  • Overdose may cause drowsiness, lightheadedness, dizziness, somnolence, respiratory depression, seizures, rostral progression of hypotonia and loss of consciousness progressing to coma.
  • Use with caution in patients with psychotic disorders, schizophrenia or confusional states as it may exacerbate condition(s).
  • Fatalities have been reported with intrathecal baclofen use.
  • Caution should be used in patients with a history of autonomic dysreflexia.
  • Presence of infection may increase the risk of surgical complication and complicate dosing of Gablofen.
  • May cause drowsiness: use caution in operation of automobiles, dangerous machinery and activity that may be hazardous by decreased alertness. Other CNS depressants and alcohol may add to this effect.
  • Potential development of intrathecal mass formation. Clinicians should monitor for signs and symptoms of new neurologic symptoms including the use of imaging diagnostic modalities.
  • Oral baclofen use has been associated with a dose-related increase in incidence of ovarian cysts.

ADVERSE REACTIONS

  • Serious Adverse Reactions
    • Sudden withdrawal of Gablofen can result in serious complications that include high fever, confusion, muscle stiffness, multiple organ-system failure, and death. Inform patients that early symptoms of Gablofen withdrawal may include increased spasticity, itching, and tingling of extremities. If Gablofen withdrawal or a pump malfunction is suspected, patients should be brought immediately to a hospital for assessment and treatment.
    • Gablofen overdose may occur suddenly or insidiously, and symptoms may include confusion, drowsiness, lightheadedness, dizziness, slow or shallow breathing, seizures, loss of muscle tone, loss of consciousness, and coma.
    • Other serious adverse events may include: potential development of intrathecal mass formation, drainage, infection, meningitis, unmanageable trunk control, CSF leakage, coma and death.
  • Common Adverse Reactions
    • The most common adverse reactions in patients with spasticity of spinal origin were hypotonia (25.3%), somnolence (20.9%), dizziness, nausea/vomiting, hypotension, headache, and convulsions.
    • The most common adverse reactions in patients with spasticity of cerebral origin were hypotonia (34.7%), somnolence (18.7%), headache (10.7%), agitation, constipation, leukocytosis, chills, and urinary retention.
    • Other common adverse events may include hypoventilation, hypertonia, paresthesia, increased salivation, back pain, pruritus, diarrhea, peripheral edema, asthenia, pain, confusion, speech disorder, amblyopia, accidental injury, and dry mouth.

USE IN SPECIFIC POPULATIONS

  • Pregnancy Category C. The effect of baclofen in labor and delivery is unknown.
  • Breastfeeding: Baclofen is excreted into breast milk at oral therapeutic doses.
  • Pediatric use: Safety and effectiveness in pediatric patients below the age of 4 years have not been established.
Important Risk Information View Full